Guangzhou Huajin Pharmaceutical Technology
Oncolytic bacteria technology for broad-spectrum solid tumor treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Series B | |
| Total Funding | 000k | ||
Guangzhou Huajin Pharmaceutical Technology (Sinogen) is a biopharmaceutical company established in 2016, focused on developing and producing innovative biological drugs for oncology. The company was co-founded by four distinguished experts returning from the United States, including Dr. Allan Zijian Zhao, who serves as the Chairman and CEO, and Dr. Li Fanghong, the COO. These founders bring extensive international experience in drug research, development, manufacturing, quality control, and clinical trials.
The company's core technology is a rapid, broad-spectrum oncolytic bacteria platform. Its lead product, SGN1 (also known as SalMet-Vec®), is a genetically engineered biologic that uses attenuated Salmonella vectors to carry and express methioninase. This mechanism precisely targets the metabolic pathways of tumors that depend on the amino acid methionine for growth. The drug is designed to treat a wide variety of malignant solid tumors and can be administered through multiple routes, including intravenously.
Sinogen has advanced SGN1 through preclinical studies and has established GMP-compliant manufacturing facilities. The product has received Investigational New Drug (IND) approvals from the U.S. FDA, China's NMPA, and Taiwan's FDA. Following these approvals, the company has initiated international multi-center Phase I/IIa clinical trials across the United States, mainland China, and Taiwan to evaluate the drug's efficacy on various solid tumors. The business operates in the innovative biopharmaceutical market, specifically targeting oncology and rare diseases. Its business model revolves around the research, development, and eventual commercialization of its proprietary drug pipeline. To fund its intensive R&D and clinical trials, the company has successfully raised significant capital through multiple financing rounds, including a Series B round in late 2023 to support the ongoing international clinical studies of SGN1.
Keywords: oncolytic bacteria, biological oncology drugs, solid tumor treatment, cancer metabolism, biopharmaceuticals, SGN1, SalMet-Vec, clinical trials, oncology R&D, gene therapy, immunotherapy, methioninase, Salmonella vector, targeted therapy, malignant tumors, IND approval, drug development, pharmaceutical manufacturing, cancer research, preclinical studies, GMP facilities, biotechnology, amino acid metabolism